多发性骨髓瘤患者在接受BCMA特异性CAR-T治疗后挽救治疗的结果:LEGEND-2的回顾性分析
该回顾性分析纳入LEGEND-2一期研究西安站点45例接受LCAR-B38M CAR-T治疗后进展的复发/难治多发性骨髓瘤患者,34例(76%)为进展性疾病。挽救治疗总缓解率50.0%,中位无进展生存期16.3个月;以蛋白酶体抑制剂为基础的联合方案中位无进展生存期长于第二次BCMA CAR-T或化疗。
要点
- LCAR-B38M CAR-T后进展患者挽救治疗总缓解率50.0%,中位无进展生存期16.3个月。
- 蛋白酶体抑制剂为基础方案中位无进展生存期28.2个月,优于第二次BCMA CAR-T的3.9个月和化疗的1.67个月。
- 基线有髓外病变者(11例)CAR-T后均进展,挽救治疗总缓解率25.0%,中位无进展生存期9.7个月。
核心结论
- 接受LCAR-B38M CAR-T细胞治疗后进展的多发性骨髓瘤患者,挽救治疗疗效中等,以蛋白酶体抑制剂为基础的挽救方案结局更好。
研究设计与样本
- 对LEGEND-2一期研究(NCT03090659)西安站点入组患者进行回顾性分析,分析接受LCAR-B38M CAR-T治疗后进展的复发/难治多发性骨髓瘤患者首个挽救治疗线及结局。
- 45例符合条件患者中34例(76%)为进展性疾病。
主要发现
- 挽救治疗总缓解率为50.0%。
- 开始挽救治疗后中位无进展生存期为16.3个月。
- 接受以蛋白酶体抑制剂为基础的联合治疗患者中位无进展生存期为28.2个月,长于接受第二次BCMA CAR-T(包括LCAR-B38M)者的3.9个月(p=0.0022)和接受化疗者的1.67个月(p=0.0001)。
- 基线有髓外病变的全部11例患者CAR-T治疗后均进展,挽救治疗总缓解率为25.0%,中位无进展生存期为9.7个月。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) has shown profound efficacy and manageable toxicity in patients with relapsed/refractory multiple myeloma (RRMM). However, determining the best course of treatment for post-CAR-T therapy relapse remains a significant challenge. We conducted a retrospective analysis of patients from the phase I LEGEND-2 study (NCT03090659) enrolled at the Xi'an site, analysing the first salvage line of therapy and outcomes in patients with RRMM who progressed after receiving LCAR-B38M CAR-T therapy. Of 45 eligible patients, 34 (76%) had progressive disease (PD). Overall response rate (ORR) to salvage treatment was 50.0%. Median progression-free survival (PFS) after starting salvage treatment was 16.3 months. Median PFS of patients receiving proteasome inhibitor (PI)-based combination therapy was longer (28.2 months) than that of patients receiving a second BCMA CAR-T (including LCAR-B38M; 3.9 months, p = 0.0022) or chemotherapy (1.67 months, p = 0.0001). All patients with extramedullary disease at baseline (n = 11) progressed after CAR-T therapy; ORR to salvage therapy was 25.0% and median PFS was 9.7 months. In conclusion, salvage therapy in patients with PD after receiving LCAR-B38M CAR-T cells produced moderate efficacy, with better outcomes for PI-based salvage regimens.
引用
- Liu R, Yang R, Xu X, et al. Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA-specific CAR-T therapy: A retrospective analysis of LEGEND-2. Br J Haematol. 2024. PMID: 38369805. doi:10.1111/bjh.19340
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。